PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis
Recruiting
The goal of this observational study is to increase the understanding of the safety and performance of Merit Medical's HeRO Graft System (HeRO) and Super HeRO Adaptor and Support Seal System (Super HeRO) devices. This study includes adults that are being treated with one of these devices as part of their regular medical care for maintaining long-term dialysis access when all other dialysis access options have failed. If participants in the study are not seen for a standard of care clinic visit d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Sarasota Memorial Health Care System, Sarasota, Florida +2 locations
Conditions: End Stage Renal Disease, Hemodialysis Access Failure
tFUS Induced Transient Scotoma for Individual Dosing
Recruiting
The purposes of this research study is to: 1. Develop a technique of transcranial Focused Ultrasound Stimulation (tFUS) where meaningful effects on the brain can be easily measured. 2. Use this technique to measure threshold for effective tFUS in individuals. 3. Determine whether disruption of conscious visual detection, versus non-conscious visually-guided behavior have different thresholds for disruption with tFUS.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/31/2025
Locations: Medical University of South Carolina Brain Stimulation Division, Charleston, South Carolina
Conditions: Healthy
Investigation of Skin Pigmentation Effect on Performance of Masimo Pulse Oximetry (INSPIRE)
Recruiting
The objective of this study is to evaluate the performance of Masimo RD SET® SpO2 sensors in subjects with light and dark skin pigmentation in the intensive care therapeutic area.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
07/31/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Hypoxemia
Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
Recruiting
To learn if pemigatinib in combination with atezolizumab and bevacizumab can help to control cholangiocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cholangiocarcinoma, FGFR2 Fusion
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
Recruiting
This study will evaluate whether ofatumumab is excreted at quantifiable levels and at which concentrations in breast milk of lactating women with RMS). The study will include lactating mothers who plan to breastfeed and initiate/re-initiate ofatumumab 2-24 weeks post-partum.
Gender:
FEMALE
Ages:
Between 18 years and 100 years
Trial Updated:
07/31/2025
Locations: UCSF, San Francisco, California +16 locations
Conditions: Multiple Sclerosis
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
Recruiting
This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Arizona Oncology Associates, PC, Tucson, Arizona +61 locations
Conditions: Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
Personalized Exercise Treatments for Older Veterans With Motoric Cognitive Risk Syndrome
Recruiting
This study will begin to evaluate personalized preventative dementia treatments for Veterans at risk for developing dementia. The investigators will target Veterans with Motoric Cognitive Risk syndrome (MCR), which is characterized by slow gait speed and cognitive concerns (e.g., problems with memory or concentrations).
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/31/2025
Locations: VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts
Conditions: Motoric Cognitive Risk Syndrome
Letrozole and Misoprostol for Early Pregnancy Loss Management
Recruiting
A pilot cohort study to preliminarily investigate the efficacy of pretreatment with letrozole 10 mg daily for three consecutive days followed by treatment with misoprostol 800 mcg vaginally for medical management of early pregnancy loss in a US population. Patients will be followed to assess efficacy of this treatment regimen, as well as additional interventions needed, side effects, adverse events, and patient acceptability.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: PEACE / Penn Medicine, Philadelphia, Pennsylvania
Conditions: Early Pregnancy Loss, Miscarriage in First Trimester, Miscarriage
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Recruiting
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
07/31/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents
Recruiting
Background: Hypereosinophilic syndrome (HES) is a blood disorder that causes high levels of white blood cells called eosinophils. HES can damage the lungs and airways, intestines, skin, and other organs. The current primary treatment for HES can cause serious side effects. Secondary treatments do not work in all people. Objective: To test an approved drug (dupilumab), combined with other drugs, in people with HES. Eligibility: People aged 18 years and older who take drugs (mepolizumab, resl... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Hypereosinophilic Syndrome
A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.
Recruiting
This pilot study is proposing a novel approach to directly target intestinal oxalate absorption with the drug Tenapanor, which was recently FDA-approved for treating hyperphosphatemia in patients with chronic kidney disease. Tenapanor works by blocking paracellular phosphate absorption by the intestine, but the underlying mechanisms have not been clearly defined. Since phosphate and oxalate ions are absorbed through the same paracellular pathway, and are of similar size and charge, Tenapanor is... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/31/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Hyperoxaluria
BeSMART Secure Storage Counseling in the Inpatient Setting
Recruiting
Firearm injuries are the leading cause of death for American youth. While most of these deaths are homicides, approximately one third are suicides and 5% are unintentional shootings where a child gains access to an unsecured firearm and unintentionally pulls the trigger injuring or killing themselves or someone else. Secure firearm storage in the home has been shown to significantly reduce the risk of both unintentional shootings and intentional self-harm behavior. Additionally, approximately 75... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Children's Hospital Colorado, Aurora, Colorado +1 locations
Conditions: Firearm Injury, Safety Issues